Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41598-017-16658-x
DC FieldValue
dc.titleYoung onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients
dc.contributor.authorLi, F.-F
dc.contributor.authorLiu, B.-L
dc.contributor.authorYin, G.-P
dc.contributor.authorZhang, D.-F
dc.contributor.authorZhai, X.-F
dc.contributor.authorChen, M.-Y
dc.contributor.authorSu, X.-F
dc.contributor.authorWu, J.-D
dc.contributor.authorYe, L
dc.contributor.authorMa, J.-H
dc.date.accessioned2020-10-20T09:06:06Z
dc.date.available2020-10-20T09:06:06Z
dc.date.issued2017
dc.identifier.citationLi, F.-F, Liu, B.-L, Yin, G.-P, Zhang, D.-F, Zhai, X.-F, Chen, M.-Y, Su, X.-F, Wu, J.-D, Ye, L, Ma, J.-H (2017). Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients. Scientific Reports 7 (1) : 16382. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-017-16658-x
dc.identifier.issn20452322
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/178297
dc.description.abstractIt is unknown whether YOD (young onset diabetes) and LOD (late onset diabetes) require similar insulin doses for intensive insulin therapy with a metformin add-on to achieve glycemic control. We analyzed data from our two previously performed randomized, controlled open-label trials. Patients were randomized to receive either continuous subcutaneous insulin infusion (CSII) therapy or CSII combined with metformin therapy for 4 weeks. The studies concentrated on the differences in the insulin doses used for the two groups. We included 36 YOD (age < 40 yrs) and 152 LOD (age > 40 yrs) patients. YOD patients who received metformin combined with CSII therapy required significantly lower insulin doses to maintain euglycemic control compared to patients with LOD. A multivariate analysis, controlled for gender and the fasting blood concentration, was performed to determine the significance of the differences between groups, particularly with respect to the total and basal insulin doses. There was a trend toward improvement in ?-cell function and insulin resistance in terms of ?HOMA-B and ?HOMA-IR in patients with YOD compared to those with LOD. Newly diagnosed T2D patients with YOD required significantly lower insulin doses, particularly basal insulin doses, to maintain glycemic control compared to the LOD patients. © 2017 The Author(s).
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectantidiabetic agent
dc.subjectbiological marker
dc.subjectinsulin
dc.subjectmetformin
dc.subjectadult
dc.subjectblood
dc.subjectcombination drug therapy
dc.subjectfemale
dc.subjectglucose blood level
dc.subjecthuman
dc.subjectmale
dc.subjectmiddle aged
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectonset age
dc.subjectrandomized controlled trial (topic)
dc.subjecttreatment outcome
dc.subjectAdult
dc.subjectAge of Onset
dc.subjectBiomarkers
dc.subjectBlood Glucose
dc.subjectDiabetes Mellitus, Type 2
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectHumans
dc.subjectHypoglycemic Agents
dc.subjectInsulin
dc.subjectMale
dc.subjectMetformin
dc.subjectMiddle Aged
dc.subjectRandomized Controlled Trials as Topic
dc.subjectTreatment Outcome
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1038/s41598-017-16658-x
dc.description.sourcetitleScientific Reports
dc.description.volume7
dc.description.issue1
dc.description.page16382
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-017-16658-x.pdf1.09 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

6
checked on Jan 22, 2021

Page view(s)

18
checked on Jan 14, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons